FDA Panel Warns of Anemia Drug Risks
Posted on: Friday, 11 May 2007, 12:00 CDT
A U.S. Food and Drug Administration panel is warning that the popular anemia drug erythropoietin may shorten the lives of some cancer patients.
The panel says the FDA should consider prescribing it less often, for shorter periods and not at all for certain cancers, The Washington Post said Friday.
The newspaper said the panel is concerned about data from studies of breast, lung, lymphoid, and throat cancers that suggest erythropoietin caused tumor promotion and shorter survival in patients.
Erythropoietin was approved in 1988 for use in patients with kidney failure and in 1993 for use in cancer patients who become anemic from chemotherapy.
The New York Times said the drugs, known generically as darbepoetin and epoetin, are used by about a half-million U.S. cancer patients a year.
The brand name Aransep is from Amgen and Procit is from Johnson & Johnson.
One panel member said some doctors may be overprescribing the drugs because they sometimes receive more from insurers than they pay for the drugs and receive rebates from the manufacturers, The Times said.
Source: United Press International
Related Articles
- Palliative Care Intervention For Patients With Advanced Cancer
- Study Suggests Survival Benefit From Radioactive Microsphere Therapy in Patients With Colorectal Cancer Liver Metastases Who Have Failed Chemotherapy
- Exelixis Initiates Phase II Trial of XL880 in Patients With Gastric Cancer
- FDA Approves Vectibix for Patients With Colorectal Cancer
- Bronchial Colonization and Postoperative Respiratory Infections in Patients Undergoing Lung Cancer Surgery*
- Avantogen and Innovate Oncology Announce Presentation of Clinical Data Demonstrating Extended Survival in Patients With Pancreatic Cancer Treated With RP101
- Regeneron's VEGF Trap Demonstrates Positive Preliminary Results From Single-Agent Phase 1 Trial in Patients With Advanced Cancer; Results Presented at ASCO Annual Meeting on May 16, 2005
- Aphton Reports Significant Activity of IGN101 in Patients With Epithelial Cancers
- Australian Cancer Technology Reports Doubling of Mean Survival Time in Patients With Pancreatic Cancer Using RP101 With Chemotherapy Treatment
- Palliative Treatment of Painful Disseminated Bone Metastases With ^Sup 186^Rhenium-HEDP in Patients With Lung Cancer
 |
 |
User Comments (0)
RSS Feeds